0000950170-23-053406.txt : 20231016 0000950170-23-053406.hdr.sgml : 20231016 20231016070547 ACCESSION NUMBER: 0000950170-23-053406 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231013 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231016 DATE AS OF CHANGE: 20231016 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 231326191 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 8-K 1 eypt-20231013.htm 8-K 8-K







Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 13, 2023



EyePoint Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)






(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)






480 Pleasant Street


Watertown, Massachusetts



(Address of Principal Executive Offices)


(Zip Code)


Registrant’s Telephone Number, Including Area Code: (617) 926-5000



(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class




Name of each exchange on which registered

Common Stock, par value $0.001




The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 13, 2023, the Board of Directors (the “Board”) of EyePoint Pharmaceuticals, Inc. (the “Company”), upon the recommendation of the Governance and Nominating Committee of the Board, increased the size of the Board to ten (10) members and appointed Stuart Duty to fill the vacancy on the Board, effective October 16, 2023.

Mr. Duty’s compensation as a director will be consistent with the compensation provided to all of the Company’s non-employee directors. Under the Company’s current non-employee director compensation policy, Mr. Duty will receive an annual cash retainer of $45,000 for general availability and participation in meetings and conference calls of the Board, which amount will be pro-rated for 2023. Mr. Duty received an initial grant of an option to acquire 60,000 shares of common stock of the Company (the “Common Stock”), with such grant vesting in three equal annual installments commencing on the first anniversary of October 16, 2023. The option is exercisable for 10 years from the date of grant, with the same per share exercise price as the closing price of the Common Stock on the Nasdaq Global Market on October 16, 2023. The option will also be subject to the terms and conditions of the Company’s 2023 Long Term Incentive Plan, which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission (“SEC”) on June 21, 2023.

The Company also entered into an indemnification agreement with Mr. Duty in connection with his appointment to the Board. The indemnification agreement is in substantially the same form as the indemnification agreement for the other directors of the Company filed as Exhibit 10.20 to the Company’s Form 10-K filed with the SEC on March 10, 2023.

There is no arrangement or understanding between Mr. Duty and any other person pursuant to which Mr. Duty was appointed a director of the Company. There are no relationships or transactions in which Mr. Duty has or will have an interest, or was or is a party, requiring disclosure under Item 404(a) of Regulation S-K.

Item 8.01 Other Events.

On October 16, 2023, the Company issued a press release announcing the appointment of Mr. Duty to the Board and the promotion of George Elston to Executive Vice President. A copy of the press release is filed with this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.






Press Release of EyePoint Pharmaceuticals, Inc. dated October 16, 2023



Cover Page Interactive Data File (embedded within the inline XBRL document)




Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.










October 16, 2023


/s/ George O. Elston




George O. Elston
Executive Vice President and Chief Financial Officer


EX-99.1 2 eypt-ex99_1.htm EX-99.1 EX-99.1


Exhibit 99.1


EyePoint Pharmaceuticals Strengthens Board and Executive Leadership Team


Stuart Duty appointed to EyePoint’s Board of Directors –


George Elston promoted to Executive Vice President -


WATERTOWN, Mass., October 16, 2023 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases, today announced the appointment of Stuart Duty to its Board of Directors and the promotion of George Elston to Executive Vice President.


“We are excited to welcome Mr. Duty to our Board of Directors,” said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals. “Stuart is a seasoned veteran in biotech finance and investment banking, and we plan to leverage his broad expertise working with biopharmaceutical companies during this critical period of EyePoint’s development. We look forward to benefitting from his strategic insight as we continue to advance our pipeline through key milestones over the coming quarters, including the topline Phase 2 DAVIO 2 data readout for EYP-1901 in wet age-related macular degeneration (AMD) anticipated in December.”


Dr. Duker continued, “George Elston has been instrumental to EyePoint’s organizational growth, financial success, and strategic long-term vision since he joined the company four years ago. His promotion to Executive Vice President underscores the invaluable role that he has played in EyePoint’s successful track record of execution, utilizing his financial prowess to advance the company’s growing pipeline through development and to build a strong balance sheet. George also drove the acquisition of key assets for our pipeline including razuprotafib, the active drug in EYP-2301, our latest pipeline program. On behalf of the entire leadership team, we congratulate George and look forward to his continued contributions to EyePoint as we continue to build value for our shareholders during this exciting time in the company’s growth.”


Stuart Duty, Board of Directors


Stuart Duty is an experienced financial executive with over 30 years of experience in finance and investment banking. Mr. Duty has focused primarily on biotechnology and specialty pharmaceuticals clients for much of his career, advising senior executives and boards on a range of financing activities and strategic transactions. Mr. Duty was most recently a Senior Managing Director at Guggenheim Securities, LLC. Previously, he held senior roles at Piper Jaffray and Montgomery Securities, and held operating roles at Oracle Partners and Curative Technologies. Mr. Duty holds a B.A. in Biochemistry from Occidental College and an M.B.A. from Harvard Business School.


“I am delighted to join EyePoint’s Board of Directors at such an exciting time for the Company, as EYP-1901 rapidly approaches multiple upcoming data readouts in wet AMD and non-proliferative diabetic retinopathy,” said Mr. Duty. “I am inspired by and share EyePoint’s commitment to improving clinical outcomes for patients facing a great unmet need for sustained-delivery options, and I look forward to working closely with my fellow Board members to support the Company’s strategic objectives as it continues to advance its innovative ophthalmic pipeline.”


George Elston, Executive Vice President and Chief Financial Officer




“I am honored to take on this role at EyePoint as we work to bring innovative ocular solutions to patients,” said Mr. Elston. “EyePoint has built a tremendous foundation and a track record of reliable execution, and I am eager to drive the company’s continued evolution as we deliver upon EyePoint’s goal of being the leader in innovating ocular sustained-delivery treatments.”


Mr. Elston joined EyePoint in 2019 as Chief Financial Officer & Head of Corporate Development. He brings more than 30 years of experience in financial and biopharmaceutical experience, with particular expertise in financial, capital markets and corporate development initiatives. Prior to EyePoint, Mr. Elston served as Chief Financial Officer & Head of Corporate Development at Enzyvant Therapeutics, where he helped build the rare disease firm, leading to its eventual acquisition. He previously served as President and Chief Executive Officer at 2X Oncology, Inc., where he advanced the company from a spin-out into a multiprogram, clinical-stage organization, and held senior executive roles at Juniper Pharmaceuticals, Inc.; KBI Biopharma; and Optherion, Inc. Mr. Elston began his career in public accounting at PriceWaterhouseCoopers. He holds a B.B.A in Accounting from Pace University and is a Certified Public Accountant. Mr. Elston currently serves as a Board Member of the DWS – DBX ETF Trust.


Inducement Grant under Nasdaq Listing Rule 5635(c)(4)


In addition, the Company has granted stock options to purchase up to 15,000 shares of EyePoint Pharmaceuticals common stock to one new employee as an inducement award outside the Company’s 2023 Long-Term Incentive Plan. The stock options were granted on October 13, 2023. The grant was approved by the Company’s Compensation Committee and made as an inducement material to the employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option award has an exercise price of $8.10 per share, the closing price of EyePoint Pharmaceuticals’ common stock on October 13, 2023. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the employee’s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continued service with the Company through the applicable vesting dates.


About EyePoint Pharmaceuticals


EyePoint Pharmaceuticals (Nasdaq: EYPT) is a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal diseases. The Company's pipeline leverages its proprietary erodible Durasert E™ technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. The proven Durasert® drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. For more information visit www.eyepointpharma.com.



EYEPOINT SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the sufficiency of our existing cash resources into 2025; our plans and any other statements about future expectations, prospects, estimates and other matters that are dependent upon future events or developments, including statements containing the words “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be



materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes uncertainties regarding the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP-1901 as a novel sustained delivery treatment for serious eye diseases, including wet age-related macular degeneration, non-proliferative diabetic retinopathy and diabetic macular edema; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; our ability to realize the anticipated benefits of the 2023 sale of YUTIQ® to Alimera Sciences including our potential to receive additional payments from Alimera pursuant to the our agreements with Alimera; our ability to manufacture YUTIQ in sufficient quantities pursuant to our commercial supply agreements with Alimera and Ocumension Therapeutics; the success of current and future license agreements, including our agreements with Alimera, Ocumension, Equinox Science and Betta Pharmaceuticals; termination or breach of current and future license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition; market acceptance of our products, including our out-licensed products; product liability; industry consolidation; compliance with environmental laws; risks and costs of international business operations; volatility of stock price; possible dilution; the impact of instability in general business and economic conditions, including changes in inflation, interest rates and the labor market; the extent to which COVID-19 impacts our business and the medical community; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; manufacturing risks; the sufficiency of the Company’s cash resources and need for additional financing; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated, or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated, or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.



Christina Tartaglia

Stern IR

Direct: 212-698-8700



Media Contact:

Amy Phillips

Green Room Communications

Direct: 412-327-9499


GRAPHIC 3 img96707757_0.jpg GRAPHIC begin 644 img96707757_0.jpg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end EX-101.PRE 4 eypt-20231013_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 5 eypt-20231013.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 eypt-20231013_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document And Entity Information
Oct. 13, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 13, 2023
Entity Registrant Name EyePoint Pharmaceuticals, Inc.
Entity Central Index Key 0001314102
Entity Emerging Growth Company false
Securities Act File Number 000-51122
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 26-2774444
Entity Address, Address Line One 480 Pleasant Street
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code (617)
Local Phone Number 926-5000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol EYPT
Security Exchange Name NASDAQ
XML 8 eypt-20231013_htm.xml IDEA: XBRL DOCUMENT 0001314102 2023-10-13 2023-10-13 0001314102 false 8-K 2023-10-13 EyePoint Pharmaceuticals, Inc. DE 000-51122 26-2774444 480 Pleasant Street Watertown MA 02472 (617) 926-5000 false false false false Common Stock, par value $0.001 EYPT NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports eypt-20231013.htm eypt-20231013.xsd eypt-20231013_lab.xml eypt-20231013_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "eypt-20231013.htm": { "nsprefix": "eypt", "nsuri": "http://eyepointpharma.com/20231013", "dts": { "inline": { "local": [ "eypt-20231013.htm" ] }, "schema": { "local": [ "eypt-20231013.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "eypt-20231013_lab.xml" ] }, "presentationLink": { "local": [ "eypt-20231013_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_fa7e29f7-4c52-46c6-bc0a-ec61d1fdb332", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "eypt-20231013.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_fa7e29f7-4c52-46c6-bc0a-ec61d1fdb332", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "eypt-20231013.htm", "first": true, "unique": true } } }, "tag": { "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://eyepointpharma.com/20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0000950170-23-053406-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-053406-xbrl.zip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end